Delivery Order SPE2DB20D2014-SPE2DB25FA83P

Award Date 1/17/25
Potential Completion Date 1/21/25
Potential Value $10K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,603.67, is a Firm Fixed Price Delivery Order for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty medication. The contract has an ultimate completion date of January 17, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a Delivery Order valued at $31,971.06 for the medical product REBIF 44 MCG/0.5 ML SYRINGE 0.5ML. The award has an ultimate completion date of January 13, 2025. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 that serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,405.24 firm fixed-price delivery order contract is for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty medication. The contract has an ultimate completion date of March 12, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
The U.S. government's Defense Logistics Agency (DLA) awarded a delivery order contract worth $18,557.98 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Rebif 44 mcg/0.5 mL syringes, a specialty medication, with a period of performance through November 4, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML. The contract has a ceiling value of $8,202.62 and is a firm fixed price delivery order that runs through August 2024. No set-aside designation was used. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and supplier of medical products to the U.S. government. The $12,303.90 firm-fixed-price contract is for the delivery of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML, a specialty medication, to support federal healthcare programs and facilities. AmerisourceBergen holds several Indefinite Delivery Contracts (IDCs) with the DLA and other...
This is a delivery order awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical for the supply of Rebif, a multiple sclerosis medication, valued at $4,101.30. The order is a firm-fixed-price contract with a period of performance through November 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, as well as a separate $750,000 IDC with the Department...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $13,938.51 firm fixed price delivery order is for the supply of the specialty medication Rebif 44 mcg/0.5 ml syringe, with a completion date of December 27, 2022. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of...
This federal contract award is for the delivery of REBIF REBIDOSE 44 MCG/0.5 ML 0.5ML pharmaceutical products to the Defense Logistics Agency (DLA). The $12,154.39 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on July 3, 2024 with a completion date of July 5, 2024. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award is for the delivery of the pharmaceutical product REBIF REBIDOSE 44 MCG/0.5 ML 0.5ML to the Defense Logistics Agency (DLA). The $14,561.85 fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a subsidiary of the major pharmaceutical distribution company Amerisourcebergen Corporation. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the company to...
  • SPE2DB20D2014
    Indefinite Delivery Contract
  • SPE2DB20D2014-SPE2DB25FA83P
    Delivery Order

This is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,422.66, is for the supply of REBIF 44 MCG/0.5 ML SYRINGE 0.5ML medical products. The contract is a firm fixed-price delivery order with an ultimate completion date of January 21, 2025.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries through a streamlined, comprehensive contracting mechanism.

The contract award does not have a set-aside designation, indicating open competition.

Generated 4/21/25, 3:38 AM